Related Experiment Video
Updated: Mar 17, 2026
A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
Patient-derived tumor xenograft models for melanoma drug discovery
Antoneicka L Harris1, Richard W Joseph2, John A Copland3
1a Center for Clinical and Translational Sciences , Mayo Clinic College of Medicine , Rochester , MN , USA.
Introduction:
Cutaneous metastatic melanoma (MM) is an aggressive form of skin cancer, with treatment providing cures to a minority of patients. The multiple risk factors that contribute to MM development suggest that cutaneous melanomas embody a repertoire of altered genetic events requiring studies to better understand its biology in order to develop novel therapies.
Areas Covered:
Patient-derived tumor xenograft (PDTX) mouse models are noted to be superior for novel drug discovery and tumor biology studies due to their ability to maintain tumor heterogeneity and their use as real-time individualized patient models. In this review, the authors highlight the utility of PDTX models in advancing treatment options for patients with MM by creating invaluable preclinical models that exhibit patient-relevant treatment outcomes.
Expert Opinion:
There is a strong necessity to reassess current approaches in which preclinical experiments are designed and executed in order to minimize unwarranted clinical trials. With rigorously performed preclinical studies, PDTX models have the capability to effectively confirm or deny drug effective outcomes. The ability to do this, however, will demand better aids to guide experimental design, the redefining of preclinical efficacy, and the understanding that these models should be viewed as complementary to other drug prediction and efficacy tools.
Insights
Patient-derived tumor xenograft (PDTX) mouse models offer superior preclinical insights for cutaneous metastatic melanoma (MM) drug discovery. These models help predict treatment outcomes, guiding more effective clinical trial design for this aggressive skin cancer.
Area of Science:
- Oncology
- Dermatology
- Translational Medicine
Background:
- Cutaneous metastatic melanoma (MM) is an aggressive skin cancer with limited curative treatment options.
- Understanding the genetic alterations in MM is crucial for developing new therapies.
- Multiple risk factors contribute to MM development, indicating complex underlying biology.
Purpose of the Study:
- To review the utility of patient-derived tumor xenograft (PDTX) mouse models in advancing MM treatment.
- To highlight how PDTX models can improve preclinical drug discovery and tumor biology studies.
- To emphasize the role of PDTX models in creating patient-relevant preclinical outcomes.
Main Methods:
- Review of existing literature on PDTX models for cutaneous metastatic melanoma.
- Analysis of the advantages of PDTX models in maintaining tumor heterogeneity.
- Evaluation of PDTX models as real-time, individualized patient models for drug testing.
Main Results:
- PDTX models are superior for novel drug discovery and tumor biology studies in MM.
- These models maintain tumor heterogeneity and serve as individualized patient models.
- PDTX models provide patient-relevant treatment outcomes, advancing therapeutic options.
Conclusions:
- There is a need to reassess preclinical experimental design to minimize unnecessary clinical trials.
- Rigorous preclinical studies using PDTX models can effectively validate drug efficacy.
- PDTX models require better experimental design guidance and should complement other predictive tools.
More Related Videos
05:33Author Spotlight: Recreating Melanoma Complexity with Patient-Derived Organoids for Immunotherapy Evaluation
Published on: September 6, 2024
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016